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Background The Lives Saved Tool (LiST) uses estimates of the effects of inter-
ventions on cause-specific child mortality as a basis for generating
projections of child lives that could be saved by increasing cover-
age of effective interventions. Estimates of intervention effects are
an essential element of LiST, and need to reflect the best available
scientific evidence. This article describes the guidelines developed
by the Child Health Epidemiology Reference Group (CHERG) that
are applied by scientists conducting reviews of intervention effects
for use in LiST.
Methods The guidelines build on and extend those developed by the
Cochrane Collaboration and the Working Group for Grading of
Recommendations Assessment, Development and Evaluation
(GRADE). They reflect the experience gained by the CHERG inter-
vention review groups in conducting the reviews published in this
volume, and will continue to be refined through future reviews.
Presentation
of the
guidelines
Expected products and guidelines are described for six steps in the
CHERG intervention review process: (i) defining the scope of the
review; (ii) conducting the literature search; (iii) extracting infor-
mation from individual studies; (iv) assessing and summarizing
the evidence; (v) translating the evidence into estimates of inter-
vention effects and (vi) presenting the results.
Conclusions The CHERG intervention reviews represent an ambitious effort to
summarize existing evidence and use it as the basis for supporting
sound public health decision making through LiST. These efforts
will continue, and a similar process is now under way to assess
intervention effects for reducing maternal mortality.
Keywords Child survival, child mortality, interventions, modeling, projections,
efficacy, effectiveness
Introduction
An intervention is currently included in the Lives
Saved Tool (LiST) only if there is evidence that it
reduces mortality among children <5 years of age,
either directly or through effects on pregnant or
recently delivered women. Future versions of LiST
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will incorporate additional interventions and generate
projections for maternal mortality and stillbirths. The
Child Health Epidemiology Reference Group (CHERG)
conducts the technical reviews used to make these
inclusion decisions, as well as to determine the size
of the effect and associated uncertainty. This article
presents the standard guidelines for the intervention
reviews presented in this volume and that will be
applied in future CHERG intervention reviews. Our
aim is to present the guidelines in sufficient detail
to allow each review to be replicated and updated
as new evidence becomes available, and to ensure
that the results of the reviews are consistent, compa-
rable and appropriate for use in LiST.
The guidelines developed for the CHERG reviews
were based on the extensive work that has already
been done on this topic elsewhere, such as by the
Cochrane Collaboration1 and the QUOROM2 stan-
dards for meta-analysis of randomized controlled
trials. However, as the end goal of the papers was
to develop an estimate of the effect of an intervention
in reducing cause-specific mortality, the CHERG had
to develop methods to guide the systematic review,
meta-analysis, and then rules for extrapolating from
existing data to the specific outcome of interest. We
have tried to incorporate existing standards for
reviews of the scientific literature into the guidelines
whenever possible. For example, the standards set by
the Cochrane reviews1 for specifying the search pro-
cedures and the need to be explicit about the inclu-
sion and exclusion criteria used in selecting studies
for consideration are clear and widely accepted, and
we have therefore not re-invented them. In addition
we have tried to abide by the recommendations
for systematic reviews and meta-analyses laid out by
several groups such as Cochrane1, QUOROM2 in
the reporting. CHERG has also adopted the system
developed by the Working Group for Grading of
Recommendations Assessment, Development and
Evaluation (GRADE)3 as the standard to be used
in CHERG intervention reviews; we explain how
GRADE was adapted to address the specific aims
and content of the CHERG intervention reviews.
For methodological issues not addressed in existing
standards, CHERG has developed new standards
that we describe here.
Methods
Draft guidelines were prepared based on the previous
experience of CHERG, and reviewed and revised in
two meetings of the leaders of the intervention
review groups. The guidelines continue to evolve as
new issues are identified in the process of conducting
and reporting on the reviews and incorporating the
results into LiST.
Presentation of the guidelines
CHERG developed a conceptual framework for the
intervention reviews that includes six steps. Figure 1
presents these steps as sequential, but in practice they
are iterative with later steps often forcing a return to
an earlier step for further work or clarification. We
present the guidelines for each step below, beginning
with a description of the expected product followed
by an explanation of the process to be followed in
generating the product.
Step 1: Define the scope of the review
Expected product
The products of this step are clear descriptions of
(i) the health outcomes addressed; (ii) the interven-
tion(s) and (iii) the inclusion and exclusion criteria
used in the search including geographic and temporal
parameters.
Process
Defining the health outcomes
An intervention is considered for inclusion in LiST
only if there is evidence suggesting an effect on mor-
tality or severe morbidity among children <5 years of
age, including effects realized through interventions
delivered to pregnant and recently delivered women.
This effect must operate either directly on one of
the causes of death considered by LiST or indirectly
through diarrhoea incidence, stunting, severe acute
malnutrition or intrauterine growth restriction (Box
1), although evidence of effects on all-cause mortality
must also be considered. Where mortality data are
scarce, review groups also review studies that provide
evidence of effects on disease incidence, prevalence,
duration or severity/hospitalizations. Evidence of
potential harmful effects is also included as a part
of the reviews.
Defining the interventions
The review group specified the characteristics of
the intervention under review, including the range
of intervention duration, dose or other factors.
Whenever possible, reviews should focus on single
Figure 1 Steps in the CHERG intervention reviews
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preventive or treatment measures rather than inter-
vention ‘packages’, because LiST models in general
uses individual interventions and the effects are on
individuals rather than populations. For example,
LiST models the effect of treating an individual child
suffering from acute watery diarrhoea with ORS,
rather than the population-level effects of programs
to distribute and promote ORS. For this reason the
primary focus of the intervention reviews is on proxi-
mal interventions (e.g. treatment with ORS) rather
than distal strategies (e.g. mass media promotion of
ORS), although information on the levels of coverage
of proximal interventions that can be achieved
through distal strategies is important information
for setting realistic target coverage rates for the prox-
imal interventions in LiST.
Time periods
The reviews include relevant studies from all time
periods for which data are available. Methods for
taking into account how recent the data are in asses-
sing the quality of the evidence are addressed in
Step 4 below.
Geographic scope
Low-income countries account for over 99% of the
burden of maternal and child mortality worldwide.4
When sufficient studies from low-income countries
are available, and in particular those with a high
burden of the outcome addressed by the review, stu-
dies from high-income countries are excluded from
the review. Data from all countries are considered
when few or no data are available from low-income
countries. Similarly, reviews of interventions effective
against causes that vary geographically (e.g. malaria
or HIV) will focus primarily on geographic areas
where these causes of death are prevalent.
Other parameters
Individual review groups are responsible for specifying
the scope of the review with respect to other param-
eters of particular importance to the intervention
under review or its effects. For example some inter-
ventions can have a pure placebo as the control arm
of a trial while for other interventions this is not prac-
tical. The additional parameters to be included will be
defined by the intervention review groups.
Step 2: Conducting the search
Expected product
The product of this step is a description of the data-
bases and information sources that have been
searched, in sufficient detail to allow the search to
be reproduced.
Process
CHERG intervention reviews cast as wide a net as pos-
sible including published and unpublished evidence.
Full documentation of all data sources is available in
the Methods section of each report.
All searches include large publication databases such
as PubMed, Cochrane Library and the WHO Regional
Databases. When relevant, additional databases are
also included such as CAB abstracts,5 the System for
Information on Grey Literature in Europe (SIGLE),6
EMBASE,7 Web of Science8 and Popline.9
Because publication bias often excludes studies with
negative findings, review groups make special efforts
to include relevant studies available only in the grey
literature. The strategies used include searching the
System for Information on Grey Literature in Europe
(SIGLE)10 and databases that specialize in conference
abstracts, as well as less formal strategies such as
word of mouth and direct contact with the principal
investigators. Results of unpublished research are
included in a review when abstracts provide detailed
methodological descriptions or full reports are avail-
able. Reviews do not include evidence substantiated
only through personal communication.
Search terms relevant to the intervention are
included in combination with ‘morbidity’, ‘incidence’,
‘prevalence’ and ‘mortality’. All combinations of
search terms used are documented in the Methods
section of the reviews.
The overall search strategy and findings are docu-
mented using a standard flow diagram, as shown in
Figure 2. Previous reviews or meta-analyses are used
as sources for the identification of possible studies to
be included in the CHERG reviews, but each paper is
re-reviewed based on the inclusion/exclusion criteria
established by the CHERG review group and if
BOX 1
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considered for inclusion is subject to the quality
assessment procedures described in Step 4.
Reviews to date have been conducted using English
search terms, but include papers published in other
languages. CHERG is working to expand its scientific
base to include searches conducted in other lan-
guages, and especially Chinese.
Step 3: Extracting individual study
information
Expected product
The product of this step is a table that presents for
each study meeting the inclusion criteria and from
which data are abstracted, characteristics of the
study and all information needed to arrive at a judge-
ment about the quality of the study methods and the
relevance of its findings to the review.
Process
All research studies and reviews meeting the inclusion
criteria are abstracted into a rectangular data base
that can be accessed through Excel. Box 2 lists the
core variables included in the database for each
review; each review group determines the additional
items that will be abstracted for their specific review.
Each paper in this volume includes a web appendix
that contains the full database as Supplementary
Table 1. These procedures are consistent with those
recommended by GRADE.3,11
All CHERG reviews are based on abstraction of
information from studies by two independent
researchers, with discrepancies resolved by an outside
supervisor. Exceptions to the double abstraction stan-
dard are explained, and details are provided about
the steps taken to prevent, identify and correct
abstraction errors.
Step 4: Assessing and summarizing
the evidence
Expected product
The product of this step is a table summarizing the
overall quality and relevance of the available data that
have the potential to contribute to an estimate of
intervention effects, organized by health outcome.
Process
Judging the quality of individual studies
We use four categories of criteria for judging quality of
study evidence, similar but not identical to those rec-
ommended by GRADE: (i) study design; (ii) study qual-
ity; (iii) relevance to the objectives of the review and
(iv) consistency across studies. CHERG review groups
applied the first three categories to individual studies in
the database constructed in Step 3, to assign evidence
Figure 2 Standard flow diagram for CHERG intervention reviews, showing the search strategy and outcomes
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quality scores to individual studies and then considered
the consistency of findings across studies before assign-
ing an overall evidence quality score.
We adapted the GRADE process to reflect the par-
ticular needs of the CHERG intervention reviews.
Box 3 presents the specific criteria used for study
design and study quality. Even the strongest studies,
however, may not be directly relevant to the interven-
tion review. The extent to which the study findings
can be applied to the generation of effect estimates
may be compromised to a greater or lesser degree
because of variations in the health outcomes used
as dependent variables; the duration, intensity or
delivery strategy used in the intervention study; or
the extent to which the study population is compara-
ble to the women and children in low- and
middle-income countries where most deaths occur.
The evidence quality score can also be downgraded
for older studies, especially when changes in epide-
miology or context suggest that the findings may have
decreased relevance (e.g. antibiotic resistance).
Each review group makes a careful assessment of
relevance for each study and records their decisions
in Supplementary Table 1; how these judgements are
applied in awarding a final study score are explained
in detail in each paper.
The final step in judging the overall quality of evi-
dence across studies is to assess the consistency of find-
ings of an effect of the intervention on specific health
outcomes. This is discussed in detail in Step 5, but
affects Step 4 because any study that produces results
that vary widely from those of several other studies of
BOX 2
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acceptable quality is then re-examined to determine
whether the reasons for this inconsistency can be
explained. This sometimes includes contacting the
study investigators to discuss the study methods in
greater detail than is available in the written report.
The results of this part of the CHERG review paper
are presented as Table 1 and in each paper in this
volume. The table is organized by health outcome,
including all-cause under-five mortality. A single
paper may appear more than once in the table if the
BOX 3
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findings related to both all-cause and cause-specific
mortality (or severe morbidity).
Assessing the overall quality of evidence
After all the individual studies have been reviewed,
abstracted and graded, the review groups must
follow a transparent process to arrive at a judgement
about the overall quality of evidence supporting an
effect of the intervention on specific health out-
come(s). This judgement includes three separate com-
ponents: (i) the volume and consistency of the
evidence; (ii) the size of the effect, or risk ratio; and
(iii) the strength of the statistical evidence for an
association between the intervention and the health
outcome as reflected in the P-value. At this point in
the CHERG review process, each of these components
has been quantified and the remaining challenge
is combining the evidence generated from various
sources into a single, replicable estimate of effects.
Data from a single study are unlikely to provide
high-quality evidence on their own—one of the
tenets of the scientific method is that results should
be replicable (and replicated). Therefore, the produc-
tion of a point estimate of an intervention’s effect for
use in LiST requires combining information from sev-
eral studies into a single measure.
The basic approach is to take an average of the
effect estimates from the individual studies through
the use of meta-analysis methods. Standard meta-
analyses involve calculating a weighted average of
the study-specific estimates, giving more weight to
studies that contain more information. The amount
of information will depend on the sample size and
the frequency of the event of interest in the study
population among other things. Although many of
the interventions addressed by CHERG and included
in LiST have been reviewed systematically in the past
(e.g. Cochrane database), as described in Step 3 above
these, reviews will generally need to be updated to
include new evidence identified through the CHERG
reviews. For interventions for which no systematic
review has ever been published or where systematic
reviews have considered limited outcomes or used
limited study designs, systematic reviews with
meta-analysis are required as a part of the CHERG
review process.
The type of meta-analysis performed depends on the
heterogeneity of the findings across the available stu-
dies, which is assessed systematically as a part of
the CHERG process. Unexplained heterogeneity in
effects, or inconsistency in findings, is one reason to
downgrade the overall quality of evidence score as
explained in Box 3.
If there is not strong evidence of heterogeneity,
review groups perform a fixed effects meta-analysis.
This method assumes that the intervention effect is
the same in all studies included in the analysis and
calculates the point estimate for this fixed effect and
its 95% confidence interval.
If there is evidence of heterogeneity across studies, a
fixed effects meta-analysis is inappropriate. Review
groups then work to identify and understand the
causes of the heterogeneity. For example, perhaps
the variability can be explained by the use of different
study designs, such as consistent differences between
results generated by cohort studies relative to those
generated by case-control studies. In this instance, if
there was no evidence of heterogeneity across cohort
studies one might decide to perform a fixed effects
meta-analysis limited to the available cohort studies.
If there remains unexplained heterogeneity in effect,
but consistency in the direction of the effect, the
review groups conduct a random effects meta-analysis,
which assumes that the effect varies between studies
rather than being constant. In practical terms, a
random effects meta-analysis differs from a fixed
effects analysis in the weighting system it uses; a
random effects meta-analysis gives relatively more
weight to small studies than a fixed effects
meta-analysis. The interpretation of the point esti-
mate also differs—it is now the average effect across
studies—and the confidence interval around the point
estimate will be wider.
If there is unexplained heterogeneity in the effect
and the direction of the effect is positive in some
studies and negative in others, further reviews of
the evidence are conducted to clarify the reasons for
these differences before inclusion of the intervention
in LiST.
Consideration of heterogeneity should not be based
solely on point estimates. It is entirely possible that
one study among a set of 10 or more will produce a
Table 1 Sample table for presenting results of the quality assessment for individual studies (Step 4 in the CHERG inter-
vention review process)
Table 1.  Quality assessment of trials of zinc for the treatment of diarrhea 
  Quality Assessment Summary of Findings 
        Directness No of events   
No of 
studies 
(ref)  Design Limitations Consistency  
Generalizability 
to population 
of interest 
Generalizability 
to intervention 
of interest Intervention Control 
Relative 
Risk (95% 
CI)  
Outcome (Outcome specific quality 
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negative point estimate, but perhaps with a wide con-
fidence interval such that the data from the study are
compatible with a positive effect of the intervention.
For this reason, it is important to consider the uncer-
tainty in the individual study estimates and whether
the observed variation could have arisen by chance.
Assigning a grade to the overall quality of evidence
Each review group must assign an overall score
reflecting their degree of confidence in the evidence
supporting an association between an intervention
and each of the relevant health outcomes, and their
recommendation concerning inclusion of the inter-
vention in the LiST model and the effectiveness
value it should be assigned. The following guidelines
are used to promote consistency across the CHERG
review groups.
 A score of ‘high’ means that the reviewers are con-
fident of both the inclusion of the intervention in
the LiST model and the effectiveness estimate.
Although additional evidence will continue to be
incorporated, it is unlikely that new evidence will
change the inclusion of intervention in the model
or dramatically change the size of the effect
estimate.
 A score of ‘moderate’ means that the reviewers are
confident of the inclusion of the intervention in the
model and given available information are present-
ing the best estimate of effectiveness. Additional
research may alter the size of the effect but is
not likely to change the inclusion in the model.
 A score of ‘low’ means that the reviewers recom-
mend inclusion of the intervention in the model
but that the size of the benefit should continue
to be studied. Additional data are needed to
increase confidence and will likely change the
effect size.
 A score of ‘very low’ means that the reviewers do
not believe there is sufficient evidence of benefit
to recommend inclusion of the intervention in
the LiST at this time unless there are compelling
biological grounds for including the intervention.
Additional data may change this classification in
future versions of the tool.
Step 5: Translate the evidence into effect
estimates
Expected product
The product of this step is a ‘best’ estimate of the
effect of the intervention on reducing under-five mor-
tality due to a specific cause, with uncertainty
expressed as ‘lower’ and ‘higher’ estimates.
Process
Rules for generating best estimates of effect
Each of the CHERG review groups produces a recom-
mendation about whether the evidence of effect jus-
tifies inclusion of the intervention under study in
LiST, and if so, a point estimate of that effect and
associated uncertainty. None of the CHERG interven-
tion reviews conducted to date is based on evidence
drawn solely from RCTs measuring effects on
cause-specific mortality, and therefore judgements
have to be made based on data of different levels of
quality and relevance. CHERG therefore has devel-
oped a set of explicit rules to promote consistency
and reproducibility. Box 4 presents the rules govern-
ing the estimation of effects that CHERG review
groups have developed and applied to date; we
expect this list to evolve as experience is gained
through further review. All rules were developed to
be conservative, leaning toward underestimation
rather than overestimation of effects, because LiST
will be applied in real-world settings where interven-
tion quality and delivery are affected by many factors
some of which may be beyond the control of program
managers.12
Translating statistical evidence into recommendations
for LiST
Meta-analyses generate summary risk/rate/odds ratios
with associated confidence intervals, and all CHERG
review groups report these uncertainty bounds as a
standard part of their results. In addition, P-values
are reported as a useful summary of the strength of
the statistical evidence of an association between an
intervention and a health outcome under the assump-
tion of no bias due to confounding.
The product need for LiST is a point estimate with
higher and lower bounds, and a summary judgement
about inclusion of the intervention in the model.
Table 2 presents the guidelines used by CHERG
review groups to move from statistical evidence to
recommendations about inclusion of an intervention
in LiST, taking into account the number of studies
contributing to the evidence, their study designs and
the P-value emerging from the meta-analysis.
Generating expert judgements of effects
When the available evidence is insufficient to support
the generation of an estimate, the review group uses
systematic procedures based on the Delphi technique
to generate an estimate based on expert opinion.13
Standard methods for conducting a Delphi in ways
that produce reliable consensus are available else-
where;14 for the CHERG intervention reviews, two
particularly important aspects are the choice of
Delphi participants (the group should represent the
appropriate epidemiological experience in public
health settings in low-income settings) and a full doc-
umentation of how the method is applied including a
listing of all individuals who participate in the process
as a subset of the intervention review group. The
design of the Delphi process should aim to generate
conservative estimates of effects.
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Step 6: Presenting the results
Expected product
The product of this step is a written report that pro-
vides full documentation of the review methods and
results and has been reviewed for completeness by
appropriate technical experts at WHO and UNICEF,
in a format that allows readers to make comparisons
easily with other CHERG intervention review reports.
Process
Standard report elements
Although the presentation of results varies across
interventions, all reports contain the following
elements.
Definition of the intervention(s): For reviews covering
multiple interventions, separate definitions are pro-
vided for each. This is especially important for sets
of interventions that are delivered together as ‘pack-
ages’; each biological or behavioural intervention is
defined individually to avoid double counting of
effects that may be included in more than one pack-
age or review.
Explanation of rules applied and exceptions to guidelines:
The review should state clearly which of the rules
of evidence (Box 4) were applied. The application
of other parts of the guidelines is summarized with
reference to this paper to minimize repetition. Any
exception to these guidelines is justified and described
in detail.
Box summarizing conclusions, recommendations for LiST
and LiST inputs if appropriate: Each review group pre-
sents this information in a standard format at the
close of the paper, preventing any misunderstanding
of their final results and conclusions. Effect estimates
are presented for the four age categories in the
Table 2 Guidelines for interpreting statistical test results from meta-analyses
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postnatal period where possible; if insufficient data
are available to support estimates by age categories,
this is stated.
Review limitations: Major limitations in the review pro-
cess are discussed in the Analysis and results sections
of each review, but should be summarized succinctly
in the discussion as a basis for the interpretation of
the findings. Examples of important limitations
include a lack of geographic diversity in study sites
or the use of modelling to move from the measured
impact on morbidity to the estimated impact on
mortality.
Recommendations for further research: The Discussion
section of each paper includes recommendations
from the review group about priority gaps in evidence
that should be addressed.
Conclusions
The CHERG reviews of intervention effectiveness are
the result of an ambitious and innovative process for
bringing together scientists from multiple disciplines
and with specific areas of expertise to generate
state-of-the-art estimates of the extent to which indi-
vidual biological and behavioural interventions can
reduce deaths among children under five. This effort
is motivated by a shared aim of supporting sound
decision making about how best to use scarce public
health resources to reduce deaths and achieve the
Millennium Development Goals, and guided commit-
ments to the scientific principles of transparency and
replication. The guidelines presented in this article
reflect thousands of hours of experience by members
of the CHERG intervention review groups, and this is
only the beginning. Reviews of interventions for redu-
cing maternal mortality are under way now, and
additional reviews will be commissioned as further
evidence on existing interventions is produced and
new interventions are developed.
Some important methodological issues remain to be
addressed. They include the need for better estimates
of uncertainty, and greater standardization in the use
of expert judgements. CHERG will continue this work
and disseminate it widely, leading over time to more
complete use of existing evidence and clearer priori-
ties for future research.
Supplementary Data
Supplementary Data are available at IJE Online.
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